Through identifying and targeting potential biomarkers that regulate the TME, such as SEMA7A, collagen, and COX-2, we can further our understanding of contributing factors to DCIS invasion and begin to address overtreatment and anxiety in DCIS patients with safer, less toxic, interventions. This evidence concerns the gene PTGS2 and ductal breast carcinoma in situ.